Colette Shaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Colette Shaw has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Susan Shamimi-Noori
Division of Interventional Radiology, Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
2 shared publications- Armeen Mahvash
Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
1 shared publication - Baljendra S. Kapoor
Department of Radiology, Cleveland Clinic Foundation, Cleveland, OH
1 shared publication Beth Chasen
1 shared publicationCarin F. Gonsalves
Division of Interventional Radiology, Department of Radiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
1 shared publication- Chandra M. Sehgal
Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
1 shared publication
Latest Publications
- 19 October 2021
- Published by Springer Nature
- p. 395-409
Use of Iodinated and Gadolinium-Containing Contrast Media in CKD
- 19 October 2021
- Published by Springer Nature
- p. 395-409
Use of Iodinated and Gadolinium-Containing Contrast Media in CKD
- 4 January 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (12) , 4354-4360
Hepatic Vein Contrast-Enhanced Ultrasound Subharmonic Imaging Signal as a Screening Test for Portal Hypertension
Background Portal hypertension is the underlying cause of most complications associated with cirrhosis, with the hepatic venous pressure gradient (HVPG) used for diagnosis and disease progression. Subharmonic imaging (SHI) is a contrast-specific imaging technique receiving at half the transmit frequency resulting in better tissue suppression. Aims To determine whether the presence of optimized SHI signals inside the hepatic vein can be used as a screening test for portal hypertension. Methods This prospective trial had 131 patients undergoing SHI examination of portal and hepatic veins using a modified Logiq 9 scanner (GE, Waukesha, WI). Images acquired after infusion of the ultrasound contrast agent Sonazoid (GE Healthcare, Oslo, Norway) were assessed for the presence of optimized SHI signals in the hepatic vein and compared to the HVPG values obtained as standard of care. Results Of 131 cases, 64 had increased HVPG values corresponding to subclinical (n = 31) and clinical (n = 33) portal hypertension (> 5 and > 10 mmHg, respectively), and 67 had normal HVPG values (< 5 mmHg). Two readers performed independent, binary qualitative assessments of the acquired digital clips. Reader one (experienced radiologist) achieved for the subclinical subgroup sensitivity of 98%, specificity of 88%, and ROC area of 0.93 and for the clinical subgroup sensitivity of 100% and specificity of 61%, with an ROC area of 0.74. Reader two (less experienced radiologist) achieved for the subclinical subgroup sensitivity of 77%, specificity of 76%, and ROC area of 0.76 and for the clinical subgroup sensitivity of 88% and specificity of 63%, with an ROC area of 0.70. Readers agreement was of 83% with kappa value of 0.66. Conclusion The presence of optimized SHI signals inside the hepatic vein can be a qualitative screening test for portal hypertension, which could reduce the need for invasive diagnostic procedures.
- 4 January 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (12) , 4354-4360
Hepatic Vein Contrast-Enhanced Ultrasound Subharmonic Imaging Signal as a Screening Test for Portal Hypertension
Background Portal hypertension is the underlying cause of most complications associated with cirrhosis, with the hepatic venous pressure gradient (HVPG) used for diagnosis and disease progression. Subharmonic imaging (SHI) is a contrast-specific imaging technique receiving at half the transmit frequency resulting in better tissue suppression. Aims To determine whether the presence of optimized SHI signals inside the hepatic vein can be used as a screening test for portal hypertension. Methods This prospective trial had 131 patients undergoing SHI examination of portal and hepatic veins using a modified Logiq 9 scanner (GE, Waukesha, WI). Images acquired after infusion of the ultrasound contrast agent Sonazoid (GE Healthcare, Oslo, Norway) were assessed for the presence of optimized SHI signals in the hepatic vein and compared to the HVPG values obtained as standard of care. Results Of 131 cases, 64 had increased HVPG values corresponding to subclinical (n = 31) and clinical (n = 33) portal hypertension (> 5 and > 10 mmHg, respectively), and 67 had normal HVPG values (< 5 mmHg). Two readers performed independent, binary qualitative assessments of the acquired digital clips. Reader one (experienced radiologist) achieved for the subclinical subgroup sensitivity of 98%, specificity of 88%, and ROC area of 0.93 and for the clinical subgroup sensitivity of 100% and specificity of 61%, with an ROC area of 0.74. Reader two (less experienced radiologist) achieved for the subclinical subgroup sensitivity of 77%, specificity of 76%, and ROC area of 0.76 and for the clinical subgroup sensitivity of 88% and specificity of 63%, with an ROC area of 0.70. Readers agreement was of 83% with kappa value of 0.66. Conclusion The presence of optimized SHI signals inside the hepatic vein can be a qualitative screening test for portal hypertension, which could reduce the need for invasive diagnostic procedures.
- 3 May 2019
- Published by Springer Nature
- p. 237-262
Central Line Management and Intestinal Failure
- 1 November 2017
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 14 (11) , S506-S529
ACR Appropriateness Criteria ® Radiologic Management of Central Venous Access
- 1 November 2017
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 14 (11) , S506-S529
ACR Appropriateness Criteria ® Radiologic Management of Central Venous Access
- 28 September 2017
- Published by Springer Nature
- p. 1-27
Central Line Management and Intestinal Failure
- 1 June 2017
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 34 (02) , 145-166
Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data
Metastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical resection is considered the only curative treatment, yet only a minority is eligible. Patients who present with unresectable disease are treated with systemic agents and/or locoregional therapies. The latter include thermal ablation and catheter-based transarterial interventions. Thermal ablation is reserved for those with limited tumor burden. It is used to downstage the disease to enable curative surgical resection, as an adjunct to surgery, or in select patients it is potentially curative. Transarterial therapies are indicated in those with more diffuse disease. The goals of care are to palliate symptoms and prolong survival. The indications and supporting data for thermal ablation and transarterial interventions are reviewed, technical and tumor factors that need to be considered prior to intervention are outlined, and finally several cases are presented.
- 1 June 2017
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 34 (02) , 145-166
Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data
Metastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical resection is considered the only curative treatment, yet only a minority is eligible. Patients who present with unresectable disease are treated with systemic agents and/or locoregional therapies. The latter include thermal ablation and catheter-based transarterial interventions. Thermal ablation is reserved for those with limited tumor burden. It is used to downstage the disease to enable curative surgical resection, as an adjunct to surgery, or in select patients it is potentially curative. Transarterial therapies are indicated in those with more diffuse disease. The goals of care are to palliate symptoms and prolong survival. The indications and supporting data for thermal ablation and transarterial interventions are reviewed, technical and tumor factors that need to be considered prior to intervention are outlined, and finally several cases are presented.
- 1 November 2014
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 4 (5) , 124-127
Ultrasound and CT-directed liver biopsy
- 1 November 2014
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 4 (5) , 124-127
Ultrasound and CT-directed liver biopsy
- 29 February 2012
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 23 (2) , 277-280
Temporary Balloon Occlusion of the Common Hepatic Artery for Administration of Yttrium-90 Resin Microspheres in a Patient with Patent Hepatoenteric Collaterals
- 29 February 2012
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 23 (2) , 277-280
Temporary Balloon Occlusion of the Common Hepatic Artery for Administration of Yttrium-90 Resin Microspheres in a Patient with Patent Hepatoenteric Collaterals